Literature DB >> 23960952

The disc as the basis of treatment for glaucoma.

Camila Zangalli1, Shelly R Gupta, George L Spaeth.   

Abstract

The goal of the treatment of patients with glaucoma is to prevent disability or, if disability already exists, to repair the disability or at the least to prevent further disability from developing. To achieve these goals requires knowing what will happen if there is no treatment and what will happen if there is treatment. That is, one must know the possible benefits from the therapy in comparison to the damage caused by the therapy. As we will demonstrate, the classic risk factors do not provide accurate estimates of the development of disability and do not answer these two questions. The most helpful clues are provided by what the patient says, by whether the disc is damaged and by whether the disc is deteriorating. The severity of disease is best estimated by the nature of the optic disc and how it changes. This report is primarily focused on increasing the skill of the physician in being able to estimate the nature of the optic disc and how that changes. This does not, however, lessen the tremendous importance of careful history-taking and of gonioscopy. In this report, however, we focus on the evaluation of the disc. Currently disc evaluation is often not adequate because of poor examination techniques, reliance on cup/disc ratios, and reliance on the results of image analyzers. We will present here the Disc Damage Likelihood Scale, which is a user-friendly method which correlates accurately with visual field changes.

Entities:  

Keywords:  Care; Cup/disc ratio; DDLS; Glaucoma; Optic disc

Year:  2011        PMID: 23960952      PMCID: PMC3729382          DOI: 10.1016/j.sjopt.2011.07.003

Source DB:  PubMed          Journal:  Saudi J Ophthalmol        ISSN: 1319-4534


  13 in total

1.  [Intraocular pressure in normal human eyes].

Authors:  W LEYDHECKER; K AKIYAMA; H G NEUMANN
Journal:  Klin Monbl Augenheilkd Augenarztl Fortbild       Date:  1958

2.  Validity of a new disk grading scale for estimating glaucomatous damage: correlation with visual field damage.

Authors:  Atilla Bayer; Paul Harasymowycz; Jeffrey D Henderer; William G Steinmann; George L Spaeth
Journal:  Am J Ophthalmol       Date:  2002-06       Impact factor: 5.258

3.  Infrequent confirmation of visual field progression.

Authors:  Alexander C Lee; Pamela A Sample; Eytan Z Blumenthal; Charles Berry; Linda Zangwill; Robert N Weinreb
Journal:  Ophthalmology       Date:  2002-06       Impact factor: 12.079

4.  The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma.

Authors:  Mae O Gordon; Julia A Beiser; James D Brandt; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Michael A Kass
Journal:  Arch Ophthalmol       Date:  2002-06

5.  Determinants of intraocular pressure and its association with glaucomatous optic neuropathy in Chinese Singaporeans: the Tanjong Pagar Study.

Authors:  Paul J Foster; David Machin; Tien-Yin Wong; Tze-Pin Ng; Jim F Kirwan; Gordon J Johnson; Peng T Khaw; Steve K L Seah
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-09       Impact factor: 4.799

6.  Videographic measurements of optic nerve topography in glaucoma.

Authors:  J Caprioli; J M Miller
Journal:  Invest Ophthalmol Vis Sci       Date:  1988-08       Impact factor: 4.799

7.  Rate and amount of visual loss in 102 patients with open-angle glaucoma followed up for at least 15 years.

Authors:  Tarek M Eid; George L Spaeth; Anya Bitterman; William C Steinmann
Journal:  Ophthalmology       Date:  2003-05       Impact factor: 12.079

8.  Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey.

Authors:  A Sommer; J M Tielsch; J Katz; H A Quigley; J D Gottsch; J Javitt; K Singh
Journal:  Arch Ophthalmol       Date:  1991-08

9.  Development and validation of a prognostic index for 4-year mortality in older adults.

Authors:  Sei J Lee; Karla Lindquist; Mark R Segal; Kenneth E Covinsky
Journal:  JAMA       Date:  2006-02-15       Impact factor: 56.272

10.  The probability of blindness from open-angle glaucoma.

Authors:  M G Hattenhauer; D H Johnson; H H Ing; D C Herman; D O Hodge; B P Yawn; L C Butterfield; D T Gray
Journal:  Ophthalmology       Date:  1998-11       Impact factor: 12.079

View more
  6 in total

Review 1.  [Clinical evaluation of the optic disc in glaucoma].

Authors:  R Greslechner; D Spiegel
Journal:  Ophthalmologe       Date:  2016-10       Impact factor: 1.059

2.  Psychometric properties of the Glaucoma Quality of Life-15 questionnaire: Use of explanatory factor analysis.

Authors:  Hamideh Mahdaviazad; Narges Roustaei; Masoumeh Beigom Masoumpour; Mohammad Reza Razeghinejad
Journal:  J Curr Ophthalmol       Date:  2018-01-17

3.  Presumed activated retinal astrocytes and Müller cells in healthy and glaucomatous eyes detected by spectral domain optical coherence tomography.

Authors:  Hin Cheung; Brett J King; Thomas J Gast
Journal:  Ophthalmic Physiol Opt       Date:  2020-09-04       Impact factor: 3.117

4.  The disc damage likelihood scale: Diagnostic accuracy and correlations with cup-to-disc ratio, structural tests and standard automated perimetry.

Authors:  Andrea C Kara-José; Luiz Alberto S Melo; Bruno L B Esporcatte; Angelica T N H Endo; Mauro Toledo Leite; Ivan Maynart Tavares
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

5.  Association of Diopsys® Short-duration Transient Visual Evoked Potential Latency with Visual Field Progression in Chronic Glaucoma.

Authors:  Richard Trevino; William E Sponsel; Carolyn E Majcher; Joey Allen; Jeffery Rabin
Journal:  J Curr Glaucoma Pract       Date:  2018-03-01

Review 6.  Machine learning applied to retinal image processing for glaucoma detection: review and perspective.

Authors:  Daniele M S Barros; Julio C C Moura; Cefas R Freire; Alexandre C Taleb; Ricardo A M Valentim; Philippi S G Morais
Journal:  Biomed Eng Online       Date:  2020-04-15       Impact factor: 2.819

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.